

Forschungsprojekte 2021

Projets de recherche 2021

Unterstützt von: / Soutenus par:

krebsforschung schweiz
recherche suisse contre le cancer
ricerca svizzera contro il cancro
swiss cancer research

Grundlagenforschung / Recherche fondamentale			
<u>Gesuchsteller/In</u>	<u>Projektnummer</u> <u>Projekttitle</u>	<u>Dauer</u> (Monate)	<u>Betrag</u> (CHF)
<u>Candidat/e</u>	<u>Numéro du projet</u> <u>Titre du projet</u>	<u>Durée</u> (mois)	<u>Montant</u> (CHF)
Alimonti Andrea , Prof. Dr med. Istituto oncologico della Svizzera italiana (IOSI), Istituto Oncologico di Ricerca (IOR) 6500 Bellinzona	KFS-5262-02-2021 Reverting prostate cancer immunosuppression by hijacking cellular senescence	36	257 700.–
Bachmann Martin , Prof. Dr. Department for BioMedical Research (DBMR), University of Bern 3010 Bern	KFS-5246-02-2021 Intratumour immunotherapy using TLR7/8 loaded nanoparticles formulated with an inflammasome activating micron-sized particulate adjuvant (MCT) in solid murine tumour models	36	371 350.–
Boland Andreas , Prof. Molecular Biology University of Geneva 1211 Geneva	KFS-5453-08-2021 Deciphering the molecular mechanisms underlying chromosome segregation	36	363 050.–
Cejka Petr , Dr. Institute for Research in Biomedicine (IRB) 6500 Bellinzona	KFS-5397-08-2021 Understanding the basis of WRN dependency in microsatellite unstable tumours	36	360 350.–
Chijioke Obinna , Dr. Institute of Experimental Immunology University of Zurich 8057 Zurich	KFS-5292-02-2021 Novel autologous humanized tumour models and their use in target discovery for engineering cellular immunotherapy	36	372 000.–
Coppari Roberto , Prof. Cell Physiology and Metabolism University of Geneva 1211 Geneva	KFS-5253-02-2021 To determine the role of FKBP10 in colorectal cancer	36	375 000.–

Hall Michael N. , Prof. Dr. Biochemistry University of Basel 4056 Basel	KFS-5281-02-2021 Selective mTORC1 inhibition as an innovative anti-cancer approach	18	187 500.–
Held Werner , Prof. Department of Oncology University of Lausanne 1066 Epalinges	KFS-5386-08-2021 Stem cell-like T-cells in tumour immunity and immunotherapy	36	361 750.–
Jacob Francis , Dr. Department of Biomedicine University Hospital Basel 4031 Basel	KFS-5389-08-2021 Innovative ovarian cancer zPDX models for prediction of treatment regimen outcomes in precision medicine	36	346 700.–
Joyce Johanna , Prof. Department of Oncology University of Lausanne 1011 Lausanne	KFS-5280-02-2021 Microenvironmental regulation of therapeutic resistance in glioblastoma	36	361 750.–
Moor Andreas , Prof. Dr. Department of Biosystems Science and Engineering ETH Zurich 4058 Basel	KFS-5444-08-2021 In vivo CRISPR screen in metastasis-accepting organ to identify seeding-promoting and seeding-suppressing interactions	36	323 900.–
Naef Felix , Dr Institute of Bioengineering Ecole Polytechnique Fédérale de Lausanne (EPFL) 1015 Lausanne	KFS-5412-08-2021 Translation landscape of eIF5A in hepatocellular carcinoma	48	326 950.–
Pascolo Steve , PD Dr. Klinik für Dermatologie UniversitätsSpital Zürich (USZ) 8091 Zürich	KFS-5271-02-2021 Enhancing therapy of cancer using immunotherapeutic RNA nanoparticles and immune check-point inhibition	36	245 450.–
Plückthun Andreas , Prof. Dr. Biochemisches Institut Universität Zürich (UZH) 8057 Zürich	KFS-5290-02-2021 Novel approaches of targeting the RAS subfamily of small GTPases in human cancer	36	344 950.–
Radtke Freddy , Prof. Dr. EPFL-SV-ISREC Ecole Polytechnique Fédérale de Lausanne (EPFL) 1015 Lausanne	KFS-5373-08-2021 Tracking the colorectal cancer ecosystem throughout tumour progression on the single-cell level	36	372 500.–
Rätsch Gunnar , Prof. Dr. Department of Computer Science ETH Zurich 8092 Zürich	KFS-5463-08-2021 Deep molecular profiling for microbiome marker detection - informing melanoma immunotherapy	36	358 900.–

Razansky Daniel , Prof. Dr. Institute for Biomedical Engineering University of Zurich 8093 Zurich	KFS-5234-02-2021 Optoacoustic monitoring of radiotherapy response dynamics in murine models of pancreatic cancer for physiological treatment adaptation	24	245 750.–
Scharl Michael , Prof. Dr. med. Department of Gastroenterology and Hepatology University Hospital Zurich 8091 Zurich	KFS-5372-08-2021 Harnessing the potential of selected Clostridiales bacteria as therapeutic approach in colorectal cancer	36	369 150.–
Schoonjans Kristina , Prof. Laboratory of Metabolic Signaling Ecole Polytechnique Fédérale de Lausanne (EPFL) 1015 Lausanne	KFS-5379-08-2021 Targeting cancer stem cells in hepatocellular carcinoma	48	375 000.–
Sommer Lukas , Prof. Anatomisches Institut Universität Zürich (UZH) 8057 Zürich	KFS-5391-08-2021 TGF- β signalling in melanoma disease progression and targeted therapy response	36	375 000.–
Stockmann Christian , Dr. med. Anatomisches Institut Universität Zürich (UZH) 8051 Zürich	KFS-5402-08-2021 Vaccination-inspired immunotherapy to target desmoplasia and tumour fibrosis in pancreatic ductal adenocarcinoma	36	365 950.–
Surdez Didier , Prof. Faculty of Medicine University of Zurich 8008 Zurich	KFS-5422-08-2021 Identification of synthetic lethal vulnerabilities in STAG2 mutated Ewing sarcoma	36	374 900.–
Thome-Miazza Margot , Prof. Faculté de biologie et de médecine Université de Lausanne (UNIL) 1066 Epalinges	KFS-5411-08-2021 Role of MALT1-dependent cleavage of the tumour suppressor A20 in lymphomagenesis	48	326 950.–
Tugues Sonia , Dr Institute of Experimental Immunology University of Zurich 8057 Zurich	KFS-5240-02-2021 Innate lymphocyte surveillance of liver metastasis	36	365 450.–
vom Berg Johannes , Dr. Institute of Laboratory Animal Science (LTK) University of Zurich 8952 Schlieren	KFS-5306-02-2021 Elucidating mechanism of action of local, compartment locked immunotherapies in a checkpoint resistant murine brain tumour model and patient derived GB explant culture	36	372 750.–
Werner Sabine , Prof. Dr. Biology ETH Zurich 8093 Zurich	KFS-5408-08-2021 Functional characterization of the fibroblast- cancer cell cross-talk in skin cancer and its control by activin A-mDia2 signalling	36	373 100.–

Wymann Matthias Paul, Prof. Dr. Departement Biomedizin (DBM) Universität Basel 4058 Basel	KFS-5442-08-2021 Deconvolution of metabolic pathways and alleviation of adverse effects in PI3K therapy by use of covalent inhibitors	36	325 000.–
--	--	----	-----------

Klinische Forschung / Recherche clinique			
Gesuchsteller/In	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Bourquin Jean-Pierre Prof. Dr. med. Dr. nat. Abteilung Onkologie Kinderspital Zürich 8032 Zürich	KFS-5298-02-2021 Enhancer factor EP300/CREBBP and metabolic dependencies in high-risk acute lymphoblastic leukaemia	36	375 000.–
Carmona Santiago, Dr Department of Oncology Ludwig Center of Cancer Research at the University of Lausanne 1011 Lausanne	KFS-5409-08-2021 Single-cell analytics for precision immuno-oncology	36	361 750.–
De Dosso Sara, Dr Medical Oncology Istituto oncologico della Svizzera italiana (IOSI) 6500 Bellinzona	KFS-5438-08-2021 Preoperative treatment with metronidazole to evaluate the efficacy in reducing Fusobacterium nucleatum tumour colonization in patients with colorectal cancer: a proof-of-concept trial	24	121 750.–
Dibner Charna, Prof. Medicine University of Geneva 1211 Geneva	KFS-5266-02-2021 Circadian clockwork and the lung tumourigenesis in humans: underlying mechanisms and new avenues for diagnostics and treatment	36	374 950.–
Jandus Camilla, Dr med. Department of Pathology and Immunology, PATIM University of Geneva 1211 Geneva	KFS-5250-02-2021 Innate lymphoid cell (ILC)-driven immune modulation in ovarian cancer	36	369 600.–
Krebs Philippe, Prof, Dr. sc. nat. Institute of Pathology University of Bern 3008 Bern	KFS-5443-08-2021 Role of IL-33 for regulation of the bone marrow niche and fibrosis in myeloproliferative neoplasms	42	374 900.–

<p>Kurzeder Christian, Dr. Gynaecology and Gynaecologic Oncology University Hospital Basel 4031 Basel</p>	<p>KFS-5245-02-2021 Is axillary dissection necessary to determine the need for chemotherapy in patients with clinically node-positive breast cancer?</p>	42	343 450.–
<p>Läubli Heinz, Prof. Medical Oncology Department of Biomedicine University Hospital Basel 4031 Basel</p>	<p>KFS-5239-02-2021 Targeting fibroblast activation protein in patients with liver metastasis by redirection of T-cells</p>	36	373 900.–
<p>Michielin Olivier, Prof. Medical Oncology Centre hospitalier universitaire vaudois (CHUV) 1011 Lausanne</p>	<p>KFS-5261-02-2021 Digital pathology-based prognostic and predictive biomarker discovery for precision immuno-oncology</p>	36	315 250.–
<p>Müller Anne, Prof. Dr. Institut für Molekulare Krebsforschung (Doppelinstitut MeF/MNF) (IMCR) Universität Zürich (UZH) 8057 Zürich</p>	<p>KFS-5228-02-2021 Identifying and overcoming immune evasion strategies of diffuse large B-cell lymphoma</p>	36	375 000.–
<p>Nardelli Haefliger Denise PD Dr phil. II Service d'urologie Centre hospitalier universitaire vaudois (CHUV) 1011 Lausanne</p>	<p>KFS-5237-02-2021 Influence of the microbiota on high risk non- muscle invasive bladder cancer and BCG immunotherapy</p>	36	359 450.–
<p>Pauli Chantal, Ass. Prof. Department for Pathology and Molecular Pathology University Hospital Zurich 8006 Zurich</p>	<p>KFS-5270-02-2021 Uncover therapeutic vulnerabilities in cancer of unknown primary (CUP) by using patient- derived tumour organoids (PDTO), in-depth molecular profiling and pharmacotyping</p>	36	339 650.–
<p>Poyet Cédric, PD Dr. med. Klinik für Urologie UniversitätsSpital Zürich (USZ) 8091 Zürich</p>	<p>KFS-5308-02-2021 Towards individualization of bladder cancer therapy: the role of microbiome in BCG responsiveness prediction</p>	42	241 050.–
<p>Pruschy Martin, Prof. Dr. sc. nat. Departement für Radio-Onkologie UniversitätsSpital Zürich (USZ) 8091 Zürich</p>	<p>KFS-5301-02-2021 Radioimmunotherapy-treated primary tumours prime secondary tumours to treatment</p>	36	374 650.–
<p>Rossi Davide, Dr Lymphoma & Genomics Research Program Institute of Oncology Research (IOR) 6500 Bellinzona</p>	<p>KFS-5257-02-2021 Reprogramming the splenic marginal zone lymphoma-educated microenvironment to RESTORE immune surveillance</p>	36	367 300.–

Rossi Lorenzo , Dr Oncology and Hematology Istituto oncologico della Svizzera italiana (IOSI) 6500 Bellinzona	KFS-5249-02-2021 SIESTA: a pilot study to investigate and evaluate poor sleep quality in cancer patients following hormonal therapeutic approaches: breast cancer survivors receiving endocrine therapy	24	168 400.–
Schmid Jérôme , Prof. Technique en radiologie médicale Haute école de santé - Genève 1206 Genève	KFS-5460-08-2021 SUBREAM: smart and ultrafast breast MR imaging for cancer detection	36	227 750.–
Schwaller Jürg , Prof. Dr. med. Departement Biomedizin DBM Universitäts-Kinderspital beider Basel (UKBB) 4031 Basel	KFS-5267-02-2021 Modelling, mechanisms and targeting of human acute erythroleukaemia	36	371 600.–
von Garnier Christophe , Prof. Dr. med. Medicine Centre hospitalier universitaire vaudois (CHUV) 1011 Lausanne	KFS-5433-08-2021 An integrative approach to identify biological and clinical biomarkers for the prediction of immune-mediated pulmonary toxicity in lung cancer patients treated with immune checkpoint inhibitors	36	288 050.–

Psychosoziale Forschung / Recherche psychosociale			
Gesuchsteller/In	Projektnummer Projekttitle	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Roser Katharina , Dr. Department of Health Sciences and Medicine University of Lucerne 6002 Lucerne	KFS-5384-08-2021 The long shadow of childhood cancer: socio-bureaucratic hardships after childhood cancer from the perspective of parents, survivors, and legal, healthcare, and insurance experts in Switzerland	36	350 850.–

Epidemiologische Forschung / Recherche épidémiologie			
Gesuchsteller/In	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Ansari Marc , Prof. Dr Unité d'onco-hématologie pédiatrique Hôpitaux universitaires de Genève (HUG) 1211 Genève	KFS-5229-02-2021 RELIVE - International registry for paediatric patients with a relapsed or refractory hepatoblastoma or hepatocellular carcinoma	36	62 100.–
Bohlius Julia , PD Dr. med. Swiss TPH, Epidemiology and Public Health Swiss Tropical and Public Health Institute 4051 Basel	KFS-5415-08-2021 The South African cervical cancer screening cohort: improving cervical cancer control in women living in South Africa	36	370 800.–
Bonadies Nicolas Prof. Dr. med. Department of Haematology and Central Haematology Laboratory Inselspital Bern 3010 Bern	KFS-5230-02-2021 I-CARE for MDS: impact of guideline adherence on effectiveness and safety of health care provided to MDS patients	48	375 000.–
Iskandar Rowan , Dr Center of Excellence in Decision- Analytic Modeling and Health Economics Research sitem-insel AG 3010 Bern	KFS-5447-08-2021 Comparative effectiveness and cost- effectiveness of cervical cancer prevention policies in Zambia: mathematical model and interactive web-based learning platform	36	186 700.–
Katapodi Maria , Prof. Dr. Clinical Research Faculty of Medicine University of Basel 4055 Basel	KFS-5293-02-2021 The CASCADE II study: use of genetic information to guide cancer surveillance for hereditary breast/ovarian cancer and lynch syndrome in Switzerland	36	375 000.–
Kuehni Claudia E. Prof. Dr. med. Institut für Sozial- und Präventivmedizin (ISPM) Universität Bern 3012 Bern	KFS-5302-02-2021 Pulmonary dysfunction after childhood cancer: assessing early stage disease (Phase 2)	36	369 150.–
Petignat Patrick , Prof. Unité d'oncogynécologie chirurgicale Hôpitaux universitaires de Genève (HUG) 1211 Genève	KFS-5312-02-2021 Promoting comprehensive cervical cancer prevention and better women's health in low- and medium resource settings	36	373 800.–

<p>Rapiti Elisabetta, Prof. Geneva Cancer Registry University of Geneva 1211 Genève</p>	<p>KFS-5243-02-2021 Importance of microsatellite instability, BRAFV600E mutation and immunoscore on colorectal cancer prognosis: a population-based cohort in Geneva</p>	<p>18</p>	<p>169 350.–</p>
<p>Rohner Eliane, Dr. Institute of Social and Preventive Medicine (ISPM) University of Bern 3012 Bern</p>	<p>KFS-5441-08-2021 Cervical pre-cancer treatment failure among women living with HIV in Zimbabwe: a cohort study</p>	<p>48</p>	<p>355 150.–</p>
<p>Vokinger Kerstin Noëlle, Prof. Dr. med. et. Dr. iur. Institute of Law University of Zurich 8001 Zurich</p>	<p>KFS-5462-08-2021 Therapeutic value of new and supplemental indication approvals of cancer drugs, pricing and policy implications</p>	<p>16</p>	<p>92 250.–</p>

Stipendien 2021

Bourses 2021

Unterstützt von: / Soutenus par:

krebsforschung schweiz
recherche suisse contre le cancer
ricerca svizzera contro il cancro
swiss cancer research

Gesuchsteller/In	Projektnummer Projekttitle	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Angelillo Julien , Dr. med. Department of Pathology and Immunology University of Geneva 1211 Geneva	MD-PhD 5375-06-2021 SAMW MD-PhD Stipendium / Decipher the cross-talk between innate lymphoid cells and tumour-associated lymphatic vessels to improve anti-tumour immunity	26	146 692.–
Chriqui Louis-Emmanuel Service de chirurgie thoracique Centre hospitalier universitaire vaudois (CHUV) 1011 Lausanne	MD-PhD 5377-06-2021 SAMW MD-PhD Stipendium / Vascular and immune impact of photodynamic therapy combined to immune checkpoint inhibition in malignant pleural mesothelioma: in- sights from an intravital imaging model	36	191 553.–
Geissler Franziska , Dr. med. Department of Gynecology and Obstetrics University Hospital Basel 4031 Basel	BIL KFS-5445-08-2021 Overcoming PARP inhibitor resistance in BRCA mutated and BRCA methylated ovarian cancer Destination: Ovarian Cancer Laboratory of the Walter and Eliza Hall Institute of Medical Research (WEHI), University of Melbourne, Melbourne, AUS	18	112 000.–
Pratsinis Manolis , Dr. med. Klinik für Urologie Kantonsspital St. Gallen (KSSG) 9007 St. Gallen	BIL KFS-5248-02-2021 ABCB1 in patients with intermediate and high-risk prostate cancer and DNA repair gene defects treated with a neoadjuvant PARP inhibitor (Niraparib) prior to surgery: assessment of a potential biomarker and correlation with the pathologic response rate Destination: Department of Urologic Surgery, University of California Davis, USA	24	143 500.–

<p>Ruiz Florian Département des neurosciences cliniques Centre hospitalier universitaire vaudois (CHUV) 1011 Lausanne</p>	<p>BIL KFS-5456-08-2021 (<i>withdrawn</i>) Dissecting the molecular mechanisms driving glioblastoma heterogeneity</p> <p>Destination: James Homer Wright Pathology Laboratories, Massachusetts General Hospital, Charlestown, USA</p>	<p>24</p>	<p>108 000.–</p>
<p>Stäger Ramon, pract. med. Department of Dermatology University Hospital Zurich 8091 Zurich</p>	<p>MD-PhD 5376-06-2021 SAMW MD-PhD Stipendium / Unravelling the cellular and molecular mechanisms of epithelial skin cancer development through multimodal single cell and spatial analysis</p>	<p>34</p>	<p>179 352.–</p>


Programm zur Stärkung der onkologischen Versorgungsforschung (2020/21)

Programme de renforcement de la recherche sur les services de santé en oncologie (2020/21)

Unterstützt von: / Soutenus par:

krebsforschung schweiz
recherche suisse contre le cancer
ricerca svizzera contro il cancro
swiss cancer research

 ACCENTUS

 Krebs
Cancer
Cancro

Nationale Strategie gegen Krebs
Stratégie nationale contre le cancer
2014–2020

Gesuchsteller/In	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Clack Lauren , Prof. Dr. phil. Institut für Implementation Science in Health Care Universität Zürich 8006 Zürich	HSR-5224-11-2020 Improving organised colorectal cancer screening programmes in Switzerland: an implementation science study	24	160 950.–
Le Pogam Marie-Annick , Dr Département Epidémiologie et Services de Santé (DESS) Unisanté - Centre Universitaire de Médecine Générale et Santé Publique 1010 Lausanne	HSR-5225-11-2020 TOCCATA - Impact of the COVID-19 crisis on the quality of Cancer care in Switzerland: a controlled time-series analysis using insurance and hospital claims data	24	130 900.–
Ming Chang , Dr., Department of Clinical Research, University of Basel 4055 Basel	HSR-5222-11-2020 Machine learning techniques for personalized breast cancer prognosis – Swiss BCpro	18	69 150.–
Puhan Milo , Prof. Dr. Institut für Epidemiologie, Biostatistik und Prävention Universität Zürich, 8001 Zürich	HSR-5217-11-2020 Preoperative smoking cessation programme in cancer patients undergoing surgery: a randomized controlled trial	48	249 300.–
Rebmann Chigrinova, Ekaterina , Dr med. Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor Inselspital Bern 3010 Bern	HSR-5223-11-2020 Analysis of late survival effects, toxicity and outcome of the allogeneic hematopoietic stem cell transplantation for Non-Hodgkin lymphoma in Switzerland. Comparison with autologous stem cell transplantation	18	118 050.–

Scheinemann Katrin, Associate Prof. Dr. med. Pädiatrische Onkologie/Hämatologie, Kantonsspital Aarau AG 5001 Aarau	HSR-5219-11-2020 LENTIL - quaLity critEria iN paediaTrlc oncoLogy	36	245 300.–
--	---	----	-----------

Im [Forschungsportal](#) finden Sie Informationen zu allen Projekten, die die Stiftung Krebsforschung Schweiz und ihre Partnerorganisation Krebsliga Schweiz seit dem Jahr 2005 gefördert haben.

Dans le [portail de recherche](#), vous trouverez les informations sur tous les projets soutenus par la fondation Recherche suisse contre le cancer et son organisation partenaire, la Ligue suisse contre le cancer, depuis 2005.

Weitere Themen

Thèmes Supplémentaires

[Beispielhafte wissenschaftliche Vorhaben](#)

[Exemples de projets scientifiques](#)

[Förderprogramm Versorgungsforschung](#)

[Programme de renforcement de la recherche sur les services de santé](#)